KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2 In Vitro KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE 2 in mouse osteoblastic cells. KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC 50 ~1.2 μM ). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: male Sprague-Dawley rats (5-week-old) . Dosage: 1, 3, 10, and 30 mg/kg. Administration: Orally once daily beginning 1 day prior to neurectomy for 28 days. Result: Decreased urinary calcium excreation in the neurectomized rats only at 30 mg/kg. Form:Solid IC50& Target:Prostaglandin Receptor